IPP Bureau
Cadila Healthcare reports Q3FY22 net profit at Rs. 500.4 Cr
By IPP Bureau - February 03, 2022
The company has reported total income of Rs. 3715.8 crores during the quarter ended December 31, 2021
Granules receives ANDA approval for anti-depressant medication
By IPP Bureau - February 03, 2022
It has a total of 50 ANDA approvals from USFDA
Universal vaccination for Covid-19 irrational: AIIMS Professor
By IPP Bureau - February 03, 2022
The need is to vaccinate people who have not contracted Covid-19
Caplin Point Q3FY22 PAT at Rs 74.95 cr.
By IPP Bureau - February 03, 2022
Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.
USFDA approves first generic of Restasis
By IPP Bureau - February 03, 2022
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Dr. Reddy's set to acquire Nimbus Health
By IPP Bureau - February 03, 2022
The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients
Zydus supplies first consignment of its Covid-19 vaccine ZyCoV-D
By IPP Bureau - February 02, 2022
The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST
Alembic receives USFDA tentative approval for fesoterodine fumarate
By IPP Bureau - February 02, 2022
The tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency
Panacea Biotec sells its domestic formulations business to Mankind Pharma
By IPP Bureau - February 02, 2022
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
Windlas Biotech concludes SAHPRA audit with an all-clear sign
By IPP Bureau - February 02, 2022
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
Lupin signs deal with Axantia to market pegfilgrastim in Middle East and Africa
By IPP Bureau - February 01, 2022
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
Medix Biochemica acquires myPOLS Biotec to expand its molecular diagnostics business
By IPP Bureau - February 01, 2022
The acquisition of myPOLS Biotec complements Medix Biochemica’s leading portfolio of IVD raw materials and expands its reagent offerings for molecular diagnostics
Moderna’s Covid-19 `Spikevax’ vaccine gets full USFDA approval
By IPP Bureau - February 01, 2022
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
CAS launches major biology expansion
By IPP Bureau - February 01, 2022
The CAS SciFinder Discovery Platform expansion unlocks human-indexed insights from journals and patents in over 50 languages dating back to 1957 and 70 million biosequences curated by CAS scientists
Alembic receives USFDA approval for clarithromycin tablets
By IPP Bureau - February 01, 2022
Clarithromycin tablets USP, 250 mg and 500 mg have an estimated market size of US $ 11 million for twelve months ending September 2021 according to IQVIA
